Bicocca Open Archive

Logo unimib boa
LAPADULA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.504
EU - Europa 3.149
AS - Asia 1.465
SA - Sud America 20
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 11.148
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.391
SG - Singapore 733
IT - Italia 648
SE - Svezia 567
IE - Irlanda 558
RU - Federazione Russa 418
DE - Germania 409
HK - Hong Kong 271
CN - Cina 267
UA - Ucraina 146
GB - Regno Unito 121
CA - Canada 84
FI - Finlandia 76
VN - Vietnam 52
IN - India 47
RO - Romania 44
AT - Austria 43
TR - Turchia 33
ID - Indonesia 29
DK - Danimarca 28
FR - Francia 28
MX - Messico 28
CZ - Repubblica Ceca 19
NL - Olanda 16
BE - Belgio 15
CO - Colombia 11
IR - Iran 9
KR - Corea 7
BR - Brasile 4
CL - Cile 4
GE - Georgia 3
PH - Filippine 3
AM - Armenia 2
CH - Svizzera 2
EE - Estonia 2
EG - Egitto 2
EU - Europa 2
IL - Israele 2
KE - Kenya 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
PL - Polonia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CR - Costa Rica 1
EC - Ecuador 1
JO - Giordania 1
JP - Giappone 1
KZ - Kazakistan 1
LT - Lituania 1
NO - Norvegia 1
PT - Portogallo 1
TW - Taiwan 1
Totale 11.148
Salva come PNG Salva come JPEG
Città #
Ann Arbor 986
Singapore 645
Fairfield 575
Dublin 543
Woodbridge 488
Chandler 451
Houston 380
Ashburn 336
Frankfurt am Main 330
Wilmington 278
Hong Kong 271
New York 245
Santa Clara 233
Princeton 225
Seattle 204
Cambridge 191
Jacksonville 189
Milan 132
Dearborn 126
Altamura 109
Lawrence 109
Shanghai 64
San Diego 61
Nanjing 50
Dong Ket 44
Galati 43
Vienna 40
Lachine 36
Helsinki 32
Andover 29
Jakarta 29
Boardman 27
Rome 25
London 24
Beijing 22
Dallas 22
Pune 22
Toronto 19
Fremont 18
Los Angeles 18
Cuauhtémoc 17
Falls Church 17
Norwalk 17
Ottawa 16
Busto Arsizio 15
Guangzhou 15
Palermo 15
Brno 14
Brussels 14
Shenyang 14
Chicago 13
Hebei 13
Munich 13
Bogotá 11
Monza 11
Washington 11
Florence 10
Nanchang 10
Tianjin 10
Lissone 8
Lappeenranta 7
Shenzhen 7
Changsha 6
Detroit 6
Redmond 6
Turin 6
Bollate 5
Brescia 5
Bresso 5
Geumjeong-gu 5
Kunming 5
Loreto 5
Mountain View 5
Vijayawada 5
Como 4
Edmonton 4
Hyderabad 4
Jinan 4
Kilburn 4
Melzo 4
Ningbo 4
Olomouc 4
Padova 4
Pisa 4
San Francisco 4
Acton 3
Bologna 3
Bonndorf 3
Caserta 3
Cinisello Balsamo 3
Clearwater 3
Gradara 3
Hangzhou 3
Hounslow 3
Jiaxing 3
Kiev 3
Leawood 3
Legnano 3
Maastricht 3
Mumbai 3
Totale 8.102
Salva come PNG Salva come JPEG
Nome #
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 291
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 221
Remdesivir use in patients requiring mechanical ventilation due to COVID-19 213
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 211
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 203
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 198
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 198
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 194
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 190
The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19 187
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 173
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 173
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 171
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 171
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 171
Unmasking tuberculosis in the era of antiretroviral treatment 165
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 165
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 164
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 163
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 163
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances 161
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 151
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 150
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 149
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 148
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 146
Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: A cross-sectional observational study 145
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 138
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 135
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 133
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 127
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 125
To the editor 124
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 124
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 122
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 121
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 118
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 115
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 114
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 114
Beware of biases in observational studies on anti-spike monoclonal antibodies 114
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 111
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 110
Associations between immune depression and cardiovascular events in HIV infection 103
COVID-19 Mortality and Stress to the Hospital System From High Patient Load 100
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 96
Malassorbimento intestinale della terapia antiretrovirale in un paziente affetto da AIDS e micobatteriosi atipica disseminata 93
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: A comparison of the D: A: D CVD risk equation and general population CVD risk equations 92
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 92
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 91
Compassionate Use of Remdesivir in Children With Severe COVID-19 83
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors 75
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study 74
Pharmacotherapy of HIV: Focus on Etravirine 74
Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19 74
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART 73
Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: A single center analysis 71
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: Results from the Italian EPOKA-MASTER cohort 71
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: A case report 71
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV 70
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 70
Predictors of AIDS-defining events among advanced naïve patients after HAART 69
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 69
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 68
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 68
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER cohort 68
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 68
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals 67
Screening and management of HIV-2-infected individuals in Northern Italy 66
Imported ciprofloxacin-resistant Neisseria meningitidis 65
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients [2] 64
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 63
Unexpected viral relapses in hepatitis C virus–infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals 63
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 63
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 63
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients 62
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis 60
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts >= 200 cells/mm(3) 60
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 59
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 59
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the italian atazanavir expanded access program and master cohorts 59
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 58
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy 58
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy 57
Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study 56
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors 56
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 56
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 54
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) 54
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation 50
Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy 48
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 48
Early prone positioning does not improve the outcome of patients with mild pneumonia due to SARS-CoV-2: results from an open-label, randomised controlled trial (the EPCoT Study) 47
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 47
High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH) 44
Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once 44
Compassionate use of remdesivir for patients with severe Covid-19 44
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 43
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 43
Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss 43
Totale 10.486
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.427
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.427
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020916 0 0 0 0 89 147 156 115 146 93 106 64
2020/20211.229 44 73 102 150 104 66 83 123 117 129 81 157
2021/20221.460 67 87 362 135 62 110 30 112 58 71 122 244
2022/20232.088 259 572 194 153 137 370 19 111 172 28 49 24
2023/20241.771 62 49 87 46 211 453 347 67 181 54 32 182
2024/20252.163 277 710 590 213 373 0 0 0 0 0 0 0
Totale 11.826